Clin2
NCT06752811Possibly a fitRecruiting

Testing a new paclitaxel formula for advanced pancreatic cancer

Pancreatic Cancer Metastatic

Treatments studied

Part of Cancer clinical trials.

This trial tests a new form of the chemotherapy drug paclitaxel (called polymeric micellar paclitaxel) for people with pancreatic cancer that has spread to other parts of the body (metastatic). It's for those who haven't had any prior treatment for their metastatic cancer, and aims to see if this drug can help control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
416 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Age 18 to 75 years old.
  • Your pancreatic cancer has spread to other organs (metastatic) and has been confirmed by a biopsy or other lab test.
  • You have not received any chemotherapy, targeted therapy, immunotherapy, or radiation for your metastatic cancer.
  • You are in generally good health (able to care for yourself, up and about more than half of the day).
  • Your blood counts and kidney/liver function are within certain ranges (checked by a simple blood test).
  • You or your partner agree to use effective birth control during the study and for 6 months after the last dose.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06770439Recruiting· Phase 2
New drug plus chemotherapy for advanced pancreatic cancer

This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.

Hangzhou, Zhejiang
NCT07165951Recruiting· Phase 3
Study of new drug combo for first treatment of advanced pancreatic cancer

This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.

Hefei, Anhui
NCT06632574Recruiting· Phase 1
Paclitaxel liposomes via artery for advanced solid tumors

This trial tests a new form of paclitaxel (a chemotherapy drug) wrapped in tiny fat bubbles called liposomes. It is given directly into an artery that feeds the tumor, which may deliver the drug more effectively to the cancer. The study is for people with advanced solid tumors that can be treated this way, such as stomach, liver, pancreatic, or lung cancers.

Nanjing
NCT06199895Recruiting· Phase 2
Study of paclitaxel for patients with taxane-resistant solid tumors

This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.

Wuhan, Hubei
NCT05035147Recruiting· Phase 4
Albumin-bound paclitaxel plus gemcitabine for advanced pancreatic cancer

This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.

Tianjin, Tianjin Municipality
NCT07831330Not yet recruiting· Phase 2
Chemotherapy combination for advanced pancreatic cancer

This trial tests a combination of two chemotherapy drugs, nab-paclitaxel and gemcitabine, as the first treatment for pancreatic cancer that has spread. The goal is to shrink tumors and improve survival.

Hear when a new Pancreatic Cancer Metastatic trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.